StockData

NextCure, Inc. (NXTC) shareholders

NXTCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$6.68+0.28 (+4.37%)

Close on Nov 16, 2026Market cap $30.58MP/E –Yield 0.00%

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
37.9%
2M of 5M shares
Institutional holders
30
11 new, 7 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
19 buys · 1 sales
Net bought $1.67M

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
ADAR1 Capital Management, LLC
Joint filing with Daniel Schneeberger (15.80%)
722,41915.80%13G (passive)Jul 31, 2026
Ikarian Capital, LLC
Joint filing with Neil Shahrestani (9.99%)
502,6729.99%13G (passive) amendmentJun 30, 2026
JP Sailing Capital Ltd
Joint filing with Jianping Huang (9.90%)
455,0019.90%13G (passive)Sep 30, 2026
Ren Jinsheng
Joint filing with Simcere Zaiming, Inc. (9.40%), Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd. (9.40%) and 3 more
338,6369.40%13G (passive) amendmentDec 31, 2025
Adage Capital Management, L.P.
Joint filing with Robert Atchinson (7.67%), Phillip Gross (7.67%)
277,2027.67%13G (passive)Jun 30, 2026
Michael Cho
Joint filing with Affinity Asset Advisors, LLC (6.40%)
274,0736.40%13G (passive) amendmentJun 30, 2026
Sofinnova Venture Partners IX, L.P. ("SVP IX")
Joint filing with Sofinnova Management IX, L.L.C. ("SM IX") (7.10%), Dr. James I. Healy ("Healy") (7.10%)
222,6547.10%13D (active) amendmentDec 19, 2025
Affinity Asset Advisors, LLC
Joint filing with Affinity Healthcare Fund, LP (7.17%)
191,8827.17%13G (passive) amendmentSep 30, 2025
Devesh Gandhi
Joint filing with SilverArc Capital Management, LLC (5.02%)
176,0575.02%13G (passive)Dec 31, 2025
William Blank
Joint filing with Squadron Capital Management LLC (6.50%), Matthew Sesterhenn (6.50%) and 1 more
173,8616.50%13G (passive)Oct 21, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of NXTCValueChange% of portfolio
Ikarian Capital, LLC288,3036.30%$461.28K+50,0000.05%
Adage Capital Partners Gp, L.L.C.277,2026.06%$443.52KNew0.00%
Sofinnova Investments, Inc.222,6544.86%$356.25K–0.02%
Renaissance Technologies LLC171,2023.74%$273.92K+110,6680.00%
Vanguard Capital Management LLC156,8423.43%$250.95K−3,6310.00%
Millennium Management LLC88,1121.92%$140.98KNew0.00%
Boothbay Fund Management, LLC84,6871.85%$135.50K+15,0700.00%
Squadron Capital Management LLC64,4641.41%$103.14K−200,5360.03%
Verdad Advisers, LP60,4511.32%$96.72K+17,4960.09%
Pfizer Inc44,3470.97%$72.97K−109,0070.04%
Affinity Asset Advisors, LLC41,9600.92%$67.14K−199,8660.00%
BlackRock, Inc.37,3480.82%$59.76K+9,5550.00%
Hrt Financial LP36,4500.80%$58.00KNew0.00%
Jane Street Group, LLC32,7250.71%$52.36KNew0.00%
Geode Capital Management, LLC29,9050.65%$47.86K−1,1870.00%
Cardiff Park Advisors, LLC21,8330.48%$34.93K–0.00%
Acadian Asset Management LLC18,9820.41%$30.00K–0.00%
Vanguard Fiduciary Trust Co16,1340.35%$25.81K+1190.00%
Nomura Asset Management International Inc.12,5000.27%$20.00KNew0.00%
Virtu Financial LLC10,9910.24%$18.00KNew0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026302M37.9%11 / 85 / 71M1M
Q1 2026262M47.4%7 / 34 / 40M0M
Q4 2025242M41.5%10 / 54 / 21M0M
Q3 2025161M18.3%16 / 00 / 01M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

16 funds held NXTC in Q2 2026, 79% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of NXTCValue% of fundAs of
Vanguard Total Stock Market Index Fund123,2762.69%$197.24K0.00%Jun 30, 2026
Vanguard Extended Market Index Fund33,5660.73%$53.71K0.00%Jun 30, 2026
Fidelity Extended Market Index Fund16,2500.36%$100.75K0.00%May 31, 2026
Nomura Healthcare Fund12,5000.27%$20.00K0.00%Jun 30, 2026
iShares Micro-Cap ETF9,8510.22%$15.76K0.00%Jun 30, 2026
Fidelity Series Total Market Index Fund3,9970.09%$24.78K0.00%May 31, 2026
Fidelity Total Market Index Fund3,6340.08%$22.53K0.00%May 31, 2026
Ultra-Small Company Market Fund3,0000.07%$4.80K0.00%Jun 30, 2026
Fidelity Nasdaq Composite Index Fund2,0470.04%$12.69K0.00%May 31, 2026
1290 VT Micro Cap Portfolio7410.02%$1.19K0.00%Jun 30, 2026
Diversified Equity Alpha Master Portfolio6890.02%$1.10K0.00%Jun 30, 2026
Dimensional U.S. Core Equity 2 ETF590.00%$2450.00%Jul 31, 2026
U.S. Micro Cap Portfolio220.00%$910.00%Jul 31, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Michael RichmanPresident & CEO, Director385,8698.43%Feb 3, 2026
Udayan GuhaChief Medical Officer––Feb 3, 2026
Kevin G. ShawSr VP, General Counsel––Feb 3, 2026
Sourav KunduSr VP, Dev. & Mfg.––Feb 3, 2026
Timothy MayerChief Operating Officer––Feb 3, 2026
Steven P. CobournChief Financial Officer––Feb 3, 2026
Sol LangermannChief Scientific Officer37,3420.82%Feb 3, 2025
Elaine V. JonesDirector––Jun 22, 2026
Anne Elizabeth BorgmanDirector––Jun 22, 2026
Ellen FeigalDirector––Jun 22, 2026
Stephen W. WebsterDirector––Jun 22, 2026
John G. HoustonDirector––Jun 22, 2026
David S. KabakoffDirector62,2371.36%Jun 22, 2026
Daniel Schneeberger10% owner––Nov 13, 2026
ADAR1 Capital Management, LLC10% owner750,28916.39%Nov 13, 2026
Renhong Tang–––Aug 12, 2026
Pharmaceutical Group Ltd Simcere–––Aug 12, 2026
Jinsheng Ren–338,6367.40%Aug 12, 2026
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.–308,6366.74%Aug 12, 2026
Simcere Zaiming, Inc.–338,6367.40%Aug 12, 2026
Simcere Zaiming Pharmaceutical Co., Ltd.–––Aug 12, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
ADAR1 Capital Management, LLC
10% owner
Nov 11, 2026Buy+12,333$5.10$62.90K750,289
ADAR1 Capital Management, LLC
10% owner
Nov 6, 2026Buy+3,662$5.10$18.68K737,956
ADAR1 Capital Management, LLC
10% owner
Nov 5, 2026Buy+1,024$5.10$5.22K734,294
ADAR1 Capital Management, LLC
10% owner
Oct 27, 2026Buy+3,553$5.10$18.10K733,270
ADAR1 Capital Management, LLC
10% owner
Oct 26, 2026Buy+1,672$5.03$8.42K729,717
ADAR1 Capital Management, LLC
10% owner
Oct 23, 2026Buy+5,626$4.83$27.17K728,045
Jiangsu Simcere Zaiming Pharmaceutical Co., Ltd.
–
Aug 10, 2026Sale−30,000$6.16$184.80K308,636
ADAR1 Capital Management, LLC
10% owner
Jul 31, 2026Buy+25,000$4.98$124.50K714,416
ADAR1 Capital Management, LLC
10% owner
Jul 31, 2026Buy+3,300$4.98$16.43K689,416
ADAR1 Capital Management, LLC
10% owner
Jul 31, 2026Buy+8,003$4.80$38.41K722,419
ADAR1 Capital Management, LLC
10% owner
Jul 30, 2026Buy+100,000$4.90$490.00K608,266
ADAR1 Capital Management, LLC
10% owner
Jul 30, 2026Buy+77,850$4.96$386.14K686,116
ADAR1 Capital Management, LLC
10% owner
Jul 30, 2026Buy+25,000$4.81$120.25K508,266
ADAR1 Capital Management, LLC
10% owner
Jul 30, 2026Buy+20,000$5.00$100.00K483,266
ADAR1 Capital Management, LLC
10% owner
Jul 30, 2026Buy+20,000$5.00$100.00K463,266
ADAR1 Capital Management, LLC
10% owner
Jul 30, 2026Buy+50,000$4.97$248.50K443,266
ADAR1 Capital Management, LLC
10% owner
Jul 29, 2026Buy+1,600$5.00$8.00K393,266
ADAR1 Capital Management, LLC
10% owner
Jul 29, 2026Buy+1,810$5.00$9.05K391,666
ADAR1 Capital Management, LLC
10% owner
Jul 28, 2026Buy+6,400$4.95$31.68K389,856
ADAR1 Capital Management, LLC
10% owner
Jul 27, 2026Buy+7,798$5.00$38.99K383,456
Kevin N. Heller
Chief Medical Officer
Jul 14, 2020Option exercise+27,229$1.77$48.20K49,011
Linda Liu
SVP, Research
Nov 27, 2019Option exercise+20,745$1.21$25.10K55,234
Linda Liu
SVP, Research
Nov 27, 2019Option exercise+34,489$0.48$16.55K34,489
Sofinnova Venture Partners IX, L.P.
10% owner
Nov 15, 2019Buy+150,000$36.75$5.51M2,671,856
Sofinnova Management IX, L.L.C.
10% owner
May 13, 2019Conversion+464,599––743,358
Sofinnova Management IX, L.L.C.
10% owner
May 13, 2019Conversion+908,785––1,652,143
Sofinnova Management IX, L.L.C.
10% owner
May 13, 2019Conversion+469,713––2,121,856
Sofinnova Management IX, L.L.C.
10% owner
May 13, 2019Conversion+278,759––278,759
Sofinnova Management IX, L.L.C.
10% owner
May 13, 2019Buy+400,000$15.00$6.00M2,521,856
Stella Xu
Director
May 13, 2019Buy+125,000$15.00$1.88M1,103,570
Stella Xu
Director
May 13, 2019Conversion+978,570––978,570
Timothy M. Shannon
Director
May 13, 2019Buy+50,000$15.00$750.00K2,254,442
Timothy M. Shannon
Director
May 13, 2019Conversion+445,866––445,866
Timothy M. Shannon
Director
May 13, 2019Conversion+743,110––1,188,976
Timothy M. Shannon
Director
May 13, 2019Conversion+729,599––1,918,575
Timothy M. Shannon
Director
May 13, 2019Conversion+285,867––2,204,442
Capital GP VI LLC OrbiMed
Director, 10% owner
May 13, 2019Buy+350,000$15.00$5.25M2,711,013
Capital GP VI LLC OrbiMed
Director, 10% owner
May 13, 2019Conversion+442,438––2,361,013
Capital GP VI LLC OrbiMed
Director, 10% owner
May 13, 2019Conversion+445,866––445,866
Capital GP VI LLC OrbiMed
Director, 10% owner
May 13, 2019Conversion+743,110––1,188,976
Capital GP VI LLC OrbiMed
Director, 10% owner
May 13, 2019Conversion+729,599––1,918,575
Alexandria Venture Investments, LLC
10% owner
May 13, 2019Conversion+197,993––197,993
Chau Quang Khuong
Director
May 13, 2019Conversion+442,438––2,361,013
Chau Quang Khuong
Director
May 13, 2019Buy+350,000$15.00$5.25M2,711,013
Chau Quang Khuong
Director
May 13, 2019Conversion+445,866––445,866
Chau Quang Khuong
Director
May 13, 2019Conversion+743,110––1,188,976
Chau Quang Khuong
Director
May 13, 2019Conversion+729,599––1,918,575
X. L.P. Canaan
10% owner
May 13, 2019Conversion+743,110––1,188,976
X. L.P. Canaan
10% owner
May 13, 2019Conversion+285,867––2,204,442
X. L.P. Canaan
10% owner
May 13, 2019Conversion+729,599––1,918,575
X. L.P. Canaan
10% owner
May 13, 2019Conversion+445,866––445,866
X. L.P. Canaan
10% owner
May 13, 2019Buy+50,000$15.00$750.00K2,254,442

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
5.21%
0M shares short
Days to cover
3.0
At 0M shares a day
Change since last report
-16.7%
From 0M shares
Short volume, 20 days
33.8%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of NextCure's stock actually held short. Settlement fails (shares not delivered on time) peaked at 37,037 shares on Sep 24, 2026 over the last 90 days.

See a number that looks wrong?